|Expense ratio (net)||N/A|
|Last cap gain||N/A|
|Morningstar risk rating||N/A|
|Beta (5Y monthly)||N/A|
|5y average return||N/A|
|Average for category||N/A|
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
BARCELONA, Spain, Oct. 17, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that it has obtained the CE mark for the Procleix Panther System featuring ART.